Menu

More than 100 mesothelioma clinical trials are currently accepting patients. Active, recruiting clinical trials accept mesothelioma cancer patients who meet certain eligibility criteria. Doctors can help interested patients understand eligibility and enrollment. Accepted patients often gain access to new and emerging therapies. 


01. Actively Recruiting Clinical Trials

Mesothelioma Clinical Trials Currently Accepting Patients

Mesothelioma patients may consider participating in a clinical trial. Clinical trials are medical studies involving people. There are dozens of active clinical trials recruiting mesothelioma patients who meet the eligibility requirements.

Doctors use mesothelioma clinical studies to evaluate the safety and efficacy of new treatments. If treatments perform well in clinical trials, they can go on to become approved by the U.S. Food and Drug Administration (FDA).

One example of this is the immunotherapy combination of Opdivo® and Yervoy®. Together, these drugs proved successful in clinical trials. Researchers found the combination extended patient survival. Based upon that data, the FDA approved Opdivo® and Yervoy® for the treatment of inoperable pleural mesothelioma.

Emerging Treatments in Mesothelioma Clinical Trials

  • Cancer vaccines: A type of immunotherapy that teaches the immune system to attack cancer, much like a vaccine
  • Cryotherapy: A cancer treatment that uses extremely cold material to treat mesothelioma
  • Immunotherapy: A wide variety of treatments that use the immune system to fight cancer
  • Multimodal therapy: Various combinations of two or more mesothelioma treatments
  • Photodynamic therapy: A treatment that uses light to kill cancer cells
  • Radical surgery: Aggressive surgical removal of mesothelioma tumors

These important medical studies follow a defined process. Each mesothelioma clinical trial starts with an idea, often in a research laboratory. Treatments that perform well in the lab and in animals can move on to clinical trials testing. This is the point at which researchers allow people to volunteer to help evaluate the new treatment(s).

Mesothelioma patients with limited treatment options may be able to access new treatments through clinical trials. In fact, the American Society of Clinical Oncology (ASCO) recommends clinical trial enrollment for the following pleural mesothelioma patients:

  • Patients qualifying for a second round of systemic chemotherapy (second-line) after failure of primary chemotherapy treatment
  • Patients with mesothelioma tumors or cells in nearby lymph nodes
  • Patients qualifying for pre-surgical or post-surgical radiation therapy

Like all medical treatments, clinical trial participation comes with certain risks. Patients should discuss the potential benefits and risks of enrolling in a clinical trial with their oncologists.

Additional information on clinical trial safety, process, costs and enrollment can be found on our Clinical Trials Overview page.

02. List of Open Clinical Trials

List of Clinical Trials Recruiting Mesothelioma Patients

Provided below is a list of mesothelioma trials that are currently accepting new patients.

A Study of SGN-CD228A in Advanced Solid Tumors


Conditions: Mesothelioma

Last Updated: November 1, 2022

Status: Recruiting

Locations: Birmingham, AL. Los Angeles, CA. Chicago, IL. Winston-Salem, NC. Cleveland, OH. Portland, OR. Pittsburgh, PA. Sioux Falls, SD. Houston, TX. San Antonio, TX.

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: November 1, 2022

Status: Recruiting

Locations: Philadelphia, PA.

Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies


Conditions: Mesothelioma, Mesothelioma, Malignant, Gastrointestinal Neoplasms, Carcinoma, Peritoneal Neoplasms, Appendiceal Neoplasms

Last Updated: October 31, 2022

Status: Recruiting

Locations: Bethesda, Maryland.

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors


Conditions: Carcinoma, Neoplasms, Carcinoma, Squamous Cell, Adenocarcinoma, Neoplasms, Germ Cell and Embryonal, Mesothelioma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Carcinoma, Basal Cell, Gastrointestinal Stromal Tumors, Carcinoid Tumor, Carcinoma, Transitional Cell, Carcinoma, Adenoid Cystic, Adenocarcinoma of Lung, Teratoma, Carcinoma, Neuroendocrine, Pheochromocytoma, Seminoma, Cystadenocarcinoma, Serous, Choriocarcinoma, Carcinoma, Endometrioid, Cystadenocarcinoma, Paraganglioma, Chordoma, Hemangiosarcoma, Fibromatosis, Aggressive, Adenocarcinoma, Mucinous, Nerve Sheath Neoplasms, Trophoblastic Neoplasms, Gestational Trophoblastic Disease, Neurofibrosarcoma, Thyroid Neoplasms, Fibroma, Cystadenocarcinoma, Mucinous, Pseudomyxoma Peritonei, Vulvar Neoplasms, Sex Cord-Gonadal Stromal Tumors, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Paget Disease, Extramammary, Adenocarcinoma, Papillary, Carcinoma, Acinar Cell, Adenocarcinoma, Bronchiolo-Alveolar, Neoplasms, Unknown Primary, Mixed Tumor, Mullerian, Carcinoma, Giant Cell, Adenocarcinoma, Clear Cell

Last Updated: October 31, 2022

Status: Recruiting

Locations: Birmingham, AL. Mobile, AL. Anchorage, AK.

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining


Conditions: Esophageal Neoplasms, Mesothelioma, Mesothelioma, Malignant, Neoplasms

Last Updated: October 27, 2022

Status: Recruiting

Locations: Bethesda, Maryland.

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: October 26, 2022

Status: Recruiting

Locations: La Jolla, CA. Miami, FL. Tampa, FL. Atlanta, GA. Chicago, IL. Baltimore, MD. Boston, MA. Boston, MA. Ann Arbor, MI. Saint Louis Park, MN. New Brunswick, NJ. New York, NY. Cleveland, OH. Hershey, PA. Philadelphia, PA. Philadelphia, PA. Pittsburgh, PA. Nashville, TN. Dallas, TX. Houston, TX. Houston, TX.

Rapid Autopsy and Procurement of Cancer Tissue


Conditions: Mesothelioma, Urogenital Neoplasms

Last Updated: October 26, 2022

Status: Recruiting

Locations: Bethesda, Maryland.

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms

Last Updated: October 25, 2022

Status: Recruiting

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas


Conditions: Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant, Esophageal Neoplasms

Last Updated: October 25, 2022

Status: Recruiting

Locations: Bethesda, MD.

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)


Conditions: Carcinoma, Neoplasms, Small Cell Lung Carcinoma, Endometrial Neoplasms, Thyroid Neoplasms, Mesothelioma, Neuroendocrine Tumors, Cholangiocarcinoma, Colorectal Neoplasms, Salivary Gland Neoplasms, Carcinoid Tumor, Anus Neoplasms, Bile Duct Neoplasms, Vulvar Neoplasms, Thyroid Diseases

Last Updated: October 25, 2022

Status: Recruiting

Locations: Los Angeles, CA. Los Angeles, CA. Orlando, FL. Boston, MA. New Brunswick, NJ.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors


Conditions: Carcinoma, Merkel Cell, Carcinoma, Neoplasms, Carcinoma, Squamous Cell, Small Cell Lung Carcinoma, Mesothelioma, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma

Last Updated: October 24, 2022

Status: Recruiting

Locations: Boston, MA. Detroit, MI. Pittsburgh, PA. Houston, TX. Seattle, WA.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors


Conditions: Carcinoma, Merkel Cell, Carcinoma, Neoplasms, Carcinoma, Squamous Cell, Carcinoma, Renal Cell, Small Cell Lung Carcinoma, Mesothelioma, Nasopharyngeal Carcinoma, Carcinoma, Basal Cell, Esophageal Squamous Cell Carcinoma, Endometrial Neoplasms

Last Updated: October 21, 2022

Status: Recruiting

Locations: Hackensack, NJ. Greenville, SC. Nashville, TN.

The Registry of Oncology Outcomes Associated With Testing and Treatment


Conditions: Sarcoma, Kaposi, Carcinoma, Neoplasms, Leukemia, Leukemia, Myeloid, Multiple Myeloma, Pancreatic Neoplasms, Sarcoma, Glioblastoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Colonic Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Astrocytoma, Mesothelioma, Neuroendocrine Tumors, Fallopian Tube Neoplasms, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Osteosarcoma, Waldenstrom Macroglobulinemia, Salivary Gland Neoplasms, Carcinoid Tumor, Anus Neoplasms, Bile Duct Neoplasms, Head and Neck Neoplasms, Vulvar Neoplasms, Liposarcoma, Pheochromocytoma, Vaginal Neoplasms, Stomach Neoplasms, Chondrosarcoma, Sarcoma, Synovial, Uterine Neoplasms, Testicular Neoplasms, Tongue Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Trophoblastic Neoplasms, Gestational Trophoblastic Disease, Penile Neoplasms, Ureteral Neoplasms, Endocrine Gland Neoplasms, Multiple Endocrine Neoplasia, Laryngeal Neoplasms, Bone Neoplasms, Adrenal Gland Neoplasms, Parathyroid Neoplasms, Neoplasms, Unknown Primary, Appendiceal Neoplasms, Pharyngeal Neoplasms, Thymus Neoplasms, Brain Stem Neoplasms, Carcinoma, Adenoid Cystic

Last Updated: October 19, 2022

Status: Recruiting

Locations: Idaho Falls, ID.

A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: October 18, 2022

Status: Recruiting

Locations: Chicago, Illinois. Boston, Massachusetts. Houston, Texas.

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs


Conditions: Carcinoma, Lung Neoplasms, Mesothelioma, Cholangiocarcinoma, Pleural Effusion

Last Updated: October 17, 2022

Status: Recruiting

Locations: Columbus , GA.

Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance


Conditions: Carcinoma, Melanoma, Mesothelioma

Last Updated: October 17, 2022

Status: Recruiting

Locations: Oakland, California.

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations


Conditions: Mesothelioma

Last Updated: October 13, 2022

Status: Recruiting

Locations: Los Angeles, California. San Diego, California. Santa Monica, California. Tampa, Florida. Covington, Louisiana. New York, New York. Durham, North Carolina. Cincinnati, Ohio. Cleveland, Ohio. Columbus, Ohio. Pittsburgh, Pennsylvania. Nashville, Tennessee. Houston, Texas. Fredericksburg, Virginia. Lynchburg, Virginia. Madison, Wisconsin.

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors


Conditions: Pancreatic Cancer, Cholangiocarcinoma, Mesothelioma, Non Small Cell Lung Cancer, Cervical Cancer, Gastric Cancer, Breast Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Melanoma, Prostate Cancer, Ovarian Cancer

Last Updated: October 10, 2022

Status: Recruiting

Locations: New Haven, Connecticut. Detroit, Michigan. New York, New York. Houston, Texas.

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors


Conditions: Mesothelioma

Last Updated: October 10, 2022

Status: Recruiting

Locations: Gilbert, Arizona. Los Angeles, California. Sarasota, Florida. Grand Rapids, Michigan. Austin, Texas. Houston, Texas.

A Study of HFB200301 in Adult Patients With Advanced Solid Tumors


Conditions: Mesothelioma, Gastric Cancer, Melanoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Sarcoma, Head and Neck Squamous Cell Carcinoma

Last Updated: October 7, 2022

Status: Recruiting

Locations: Scottsdale, Arizona. Los Angeles, California. Jacksonville, Florida. Rochester, Minnesota. Saint Louis, Missouri. Houston, Texas. Fairfax, Virginia.

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas


Conditions: Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse, Mesothelioma, Mesothelioma, Malignant, Prostatic Neoplasms, Lymphoma, T-Cell, Prostatic Neoplasms, Castration-Resistant

Last Updated: October 6, 2022

Status: Recruiting

Locations: Atlanta, GA. Chicago, IL. Baltimore, MD. Boston, MA. Boston, MA. Ann Arbor, MI. Grand Rapids, MI. Hackensack, NJ. Bronx, NY. New York, NY. Cincinnati, OH. San Antonio, TX. Charlottesville, VA. Seattle, WA.

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: October 5, 2022

Status: Recruiting

Locations: Bethesda, Maryland.

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53


Conditions: Neoplasms

Last Updated: October 5, 2022

Status: Recruiting

Locations: Duarte, CA. Los Angeles, CA. Newport Beach, CA. Iowa City, IA. Ann Arbor, MI. New York, NY. Philadelphia, PA. Houston, TX. San Antonio, TX. Fairfax, VA.

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma


Conditions: Neoplasms, Mesothelioma, Mesothelioma, Malignant, Pancreatic Neoplasms, Stomach Neoplasms, Thymoma, Biliary Tract Neoplasms

Last Updated: October 5, 2022

Status: Recruiting

Locations: Bethesda, Maryland.

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma


Conditions: Any Solid Tumors, Mesothelioma, Head and Neck Squamous Cell Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Lung, Esophageal Cancer, Adenoid Cystic Carcinoma, Prostate Cancer, Cervical Cancer, Melanoma

Last Updated: September 30, 2022

Status: Recruiting

Locations: Duarte, California. New York, New York. Houston, Texas. Milwaukee, Wisconsin. Canton, Ohio.

Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant, Neoplasms, Fibrous Tissue, Solitary Fibrous Tumors, Pleural Neoplasms, Solitary Fibrous Tumor, Pleural, Hemangiopericytoma

Last Updated: September 28, 2022

Status: Recruiting

Locations: Rochester, MN.

Staging Procedures to Diagnose Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant, Neoplasms, Fibrous Tissue, Solitary Fibrous Tumors, Pleural Neoplasms, Solitary Fibrous Tumor, Pleural

Last Updated: September 28, 2022

Status: Recruiting

Locations: Rochester, MN.

Stereotactic Magnetic Resonance Guided Radiation Therapy


Conditions: Prostatic Neoplasms, Neoplasm Metastasis, Neoplasms, Second Primary, Brain Neoplasms, Mesothelioma, Pancreatic Neoplasms, Kidney Neoplasms, Carcinoma, Renal Cell

Last Updated: September 27, 2022

Status: Recruiting

Locations: Boston, MA. Boston, MA.

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors


Conditions: Neoplasms, Melanoma, Mesothelioma, Mesothelioma, Malignant, Skin Neoplasms, Lung Neoplasms, Bone Neoplasms, Genital Neoplasms, Female, Soft Tissue Neoplasms, Pharyngeal Neoplasms, Endocrine Gland Neoplasms, Mouth Neoplasms, Urologic Neoplasms, Thyroid Neoplasms, Genital Neoplasms, Male, Sarcoma, Thyroid Diseases, Recurrence

Last Updated: September 26, 2022

Status: Recruiting

Locations: Houston, TX.

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer


Conditions: Carcinoma, Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Stomach Neoplasms, Uterine Cervical Neoplasms, Mesothelioma, Mesothelioma, Malignant, Carcinoma, Transitional Cell, Endometrial Neoplasms, Bile Duct Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Penile Neoplasms

Last Updated: September 26, 2022

Status: Recruiting

Locations: Sacramento, CA. Bethesda, MD. Bethesda, MD. Columbus, OH. Pittsburgh, PA. Madison, WI. New York, NY.

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer


Conditions: Neoplasms, Adenocarcinoma, Mesothelioma, Cystadenocarcinoma, Serous

Last Updated: September 22, 2022

Status: Recruiting

Locations: Bethesda, Maryland. Nashville, Tennessee.

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms

Last Updated: September 19, 2022

Status: Recruiting

Locations: Coral Gables, FL. Deerfield Beach, FL. Miami, FL. Tampa, FL. Tampa, FL. Tampa, FL. Chicago, IL. Boston, MA. Rochester, MN. Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. New York, NY. Uniondale, NY. Cleveland, OH. Columbus, OH. Houston, TX. Seattle, WA.

Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies


Conditions: Carcinoma, Glioblastoma, Mesothelioma, Cholangiocarcinoma, Squamous Cell Carcinoma of Head and Neck

Last Updated: September 15, 2022

Status: Recruiting

Locations: Los Angeles, California. Newport Beach, California. Santa Monica, California. Sarasota, Florida. Baltimore, Maryland. Boston, Massachusetts. Grand Rapids, Michigan. Omaha, Nebraska. Greenville, South Carolina. Houston, Texas. San Antonio, Texas.

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers


Conditions: Mesothelioma

Last Updated: September 15, 2022

Status: Recruiting

Locations: Houston, Texas.

Dose Individualization of Pemetrexed - IMPROVE-I


Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant

Last Updated: September 10, 2022

Status: Recruiting

Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant, Neoplasms, Fibrous Tissue, Solitary Fibrous Tumors, Pleural Neoplasms, Solitary Fibrous Tumor, Pleural

Last Updated: September 8, 2022

Status: Recruiting

Locations: Rochester, MN.

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer


Conditions: Carcinoma, Melanoma, Mesothelioma

Last Updated: September 1, 2022

Status: Recruiting

Locations: Boston, Massachusetts.

A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: August 26, 2022

Status: Recruiting

Locations: Basking Ridge, New Jersey. Middletown, New Jersey. Montvale, New Jersey. Commack, New York. Harrison, New York. New York, New York. Rockville Centre, New York.

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma


Conditions: Mesothelioma

Last Updated: August 25, 2022

Status: Recruiting

Locations: Phoenix, AZ. Chicago, IL. Danville, IL. Effingham, IL. Matoon, IL. Urbana, IL. Lexington, KY. Boston, MA. Bemidji, MN. Edina, MN. Minneapolis, MN. Rochester, MN. Bismarck, ND. Fargo, ND. Columbus, OH. Oklahoma City, OK. Pittsburgh, PA. Sioux Falls, SD.

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors


Conditions: Mesothelioma, Locally Advanced Solid Tumor

Last Updated: August 22, 2022

Status: Recruiting

Locations: Boston, Massachusetts. Boston, Massachusetts. Nashville, Tennessee. Houston, Texas. San Antonio, Texas. Fairfax, Virginia.

APG-2449 in Patients With Advanced Solid Tumors


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: August 19, 2022

Status: Recruiting

A Beta-only IL-2 ImmunoTherapY (ABILITY) Study


Conditions: Mesothelioma

Last Updated: August 17, 2022

Status: Recruiting

Locations: Boca Raton, Florida. Orlando, Florida. Atlanta, Georgia.

Oral AMXT 1501 Dicaprate in Combination With IV DFMO


Conditions: Endometrial Neoplasms, Mesothelioma, Diffuse Intrinsic Pontine Glioma

Last Updated: August 15, 2022

Status: Recruiting

Locations: Houston, Texas.

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas


Conditions: Adenocarcinoma, Sarcoma, Mesothelioma, Mesothelioma, Malignant, Sarcoma, Ewing, Chondrosarcoma

Last Updated: August 12, 2022

Status: Recruiting

Locations: Scottsdale, AZ. Duarte, CA. Los Angeles, CA. Santa Monica, CA. Aurora, CO. Atlanta, GA. Chicago, IL. Ann Arbor, MI. Grand Rapids, MI. New York, NY. Cleveland, OH. Philadelphia, PA. Houston, TX. San Antonio, TX.

KZR-261 in Subjects With Advanced Solid Malignancies


Conditions: Mesothelioma, Neoplasms

Last Updated: August 12, 2022

Status: Recruiting

Locations: Los Angeles, California. Tampa, Florida. Atlanta, Georgia. Philadelphia, Pennsylvania. Nashville, Tennessee. San Antonio, Texas. Fairfax, Virginia.

Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion


Conditions: Mesothelioma, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma, Solid Tumor

Last Updated: August 10, 2022

Status: Recruiting

Locations: Denver, Colorado. Boston, Massachusetts. New York, New York. Nashville, Tennessee. Houston, Texas. San Antonio, Texas.

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors


Conditions: Mesothelioma

Last Updated: August 5, 2022

Status: Recruiting

Locations: Duarte, California. La Jolla, California. Aurora, Colorado. Denver, Colorado. Boston, Massachusetts. Philadelphia, Pennsylvania. San Antonio, Texas.

A Study of NX-1607 in Adults With Advanced Malignancies


Conditions: Carcinoma, Neoplasms, Triple Negative Breast Neoplasms, Mesothelioma, Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer, Carcinoma, Ovarian Epithelial

Last Updated: July 27, 2022

Status: Recruiting

Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: July 26, 2022

Status: Recruiting

Locations: Buffalo, NY. Philadelphia, PA.

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers


Conditions: Carcinoma, Merkel Cell, Mesothelioma, Neuroendocrine Tumors, Neoplasms, Squamous Cell, Carcinoma, Squamous Cell, Microsatellite Instability

Last Updated: July 22, 2022

Status: Recruiting

Locations: Pittsburgh, PA.

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: July 22, 2022

Status: Recruiting

Locations: Baltimore, MD. Baltimore, MD. Houston, TX.

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion


Conditions: Neoplasms

Last Updated: July 22, 2022

Status: Recruiting

Locations: Scottsdale, Arizona. Duarte, California. Indianapolis, Indiana. Baltimore, Maryland. Boston, Massachusetts. New York, New York. New York, New York. Oklahoma City, Oklahoma. Nashville, Tennessee. Houston, Texas. San Antonio, Texas.

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome


Conditions: Carcinoma, Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma, Meningioma, Disease Susceptibility

Last Updated: July 11, 2022

Status: Recruiting

Locations: Columbus, Ohio.

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies


Conditions: Neoplasms, Neoplasm Metastasis

Last Updated: July 11, 2022

Status: Recruiting

Locations: Grand Rapids, Michigan. Houston, Texas. San Antonio, Texas.

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery


Conditions: Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms, Pleural Diseases

Last Updated: June 21, 2022

Status: Recruiting

Locations: Buffalo, NY.

A Study of Pembrolizumab and Cryoablation in People With Mesothelioma


Conditions: Mesothelioma

Last Updated: June 16, 2022

Status: Recruiting

Locations: Basking Ridge, New Jersey. Middletown, New Jersey. Montvale, New Jersey. Commack, New York. Harrison, New York. New York, New York. Uniondale, New York.

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors


Conditions: Mesothelioma

Last Updated: June 7, 2022

Status: Recruiting

Locations: Boston, Massachusetts. Grand Rapids, Michigan. Philadelphia, Pennsylvania. Nashville, Tennessee. Houston, Texas. San Antonio, Texas.

Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: June 2, 2022

Status: Recruiting

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer


Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant, Cholangiocarcinoma

Last Updated: May 27, 2022

Status: Recruiting

Locations: San Francisco, CA. Bethesda, MD. New York, NY. Philadelphia, PA. Nashville, TN. Houston, TX.

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers


Conditions: Neoplasm Metastasis, Melanoma, Primary Myelofibrosis

Last Updated: May 20, 2022

Status: Recruiting


Conditions: Malignant Mesothelioma

Last Updated: May 19, 2022

Status: Recruiting

Surgery for Mesothelioma After Radiation Therapy Using Exquisite Systemic Therapy


Conditions: Mesothelioma

Last Updated: May 19, 2022

Status: Recruiting

Locations: Toronto, California.

Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: May 18, 2022

Status: Recruiting

Locations: Chicago, IL.

Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)


Conditions: Mesothelioma

Last Updated: May 3, 2022

Status: Recruiting

Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: April 15, 2022

Status: Recruiting

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: April 7, 2022

Status: Recruiting

Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: April 4, 2022

Status: Recruiting

Locations: New York, New York.

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: March 23, 2022

Status: Recruiting

Locations: Boston, MA.

CAR T Cells in Mesothelin Expressing Cancers


Conditions: Mesothelioma, Mesothelioma, Malignant, Fallopian Tube Neoplasms, Adenocarcinoma of Lung

Last Updated: March 10, 2022

Status: Recruiting

Locations: Philadelphia, PA.

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors


Conditions: Carcinoma, Melanoma, Mesothelioma, Oropharynx Cancer, Renal Cell Carcinoma, Solid Tumor

Last Updated: March 9, 2022

Status: Recruiting

Locations: Phoenix, AZ. Jacksonville, FL. Miami, FL. Kansas City, KS. Boston, MA. Rochester, MN. Billings, MT. Houston, TX.

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers


Conditions: Carcinoma, Merkel Cell, Lymphoma, Carcinoma, Endometrial Neoplasms, Mesothelioma, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell

Last Updated: March 4, 2022

Status: Recruiting

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma


Conditions: Mesothelioma

Last Updated: March 2, 2022

Status: Recruiting

Locations: Chicago, Illinois.

Integrated Cancer Repository for Cancer Research


Conditions: Neoplasms, Multiple Myeloma, Pancreatic Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms, Thyroid Neoplasms, Mesothelioma, Neuroendocrine Tumors, Salivary Gland Neoplasms, Anus Neoplasms, Gallbladder Neoplasms, Bile Duct Neoplasms, Oropharyngeal Neoplasms, Nasopharyngeal Neoplasms, Nasopharyngeal Carcinoma, Urethral Neoplasms, Vaginal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Adenomatous Polyposis Coli, Colorectal Neoplasms, Hereditary Nonpolyposis, Testicular Neoplasms, Intestinal Neoplasms, Hypopharyngeal Neoplasms, Penile Neoplasms, Ureteral Neoplasms, Neoplasms, Plasma Cell, Peritoneal Neoplasms, Paranasal Sinus Neoplasms, Neoplasms, Unknown Primary, Duodenal Neoplasms, Lip Neoplasms, Thymus Neoplasms, Paraproteinemias

Last Updated: February 24, 2022

Status: Recruiting

Locations: Colorado Springs, CO. Denver, CO. Durango, CO. Lakewood, CO. Littleton, CO. Longmont, CO. Louisville, CO. Parker, CO. Pueblo, CO. Westminster, CO. Daytona Beach, FL. DeLand, FL. Orange City, FL. Palm Coast, FL. Aurora, IL. Moline, IL. Yorkville, IL. Fort Wayne, IN. Indianapolis, IN. Indianapolis, IN. Indianapolis, IN. Kokomo, IN. Council Bluffs, IA. Davenport, IA. Spencer, IA. Waterloo, IA. Overland Park, KS. New Orleans, LA. Portland, ME. Randallstown, MD. Westminster, MD. Holyoke, MA. Ann Arbor, MI. Aitkin, MN. Brainerd, MN. Duluth, MN. Duluth, MN. Fergus Falls, MN. Marshall, MN. Joplin, MO. Kansas City, MO. Kansas City, MO. Kansas City, MO. Liberty, MO. Saint Joseph, MO. Kalispell, MT. Missoula, MT. Hastings, NE. Norfolk, NE. North Platte, NE. O'Neill, NE. Omaha, NE. Omaha, NE. Omaha, NE. Scottsbluff, NE. Glens Falls, NY. Utica, NY. Fayetteville, NC. Fargo, ND. Minot, ND. Pittsburgh, PA. Aberdeen, SD. Mitchell, SD. Sioux Falls, SD. Sioux Falls, SD. Yankton, SD. Yankton, SD. Yankton, SD. Rutland, VT. Fredericksburg, VA. Appleton, WI. Brookfield, WI. Franklin, WI. Mequon, WI. Milwaukee, WI. Oshkosh, WI. Racine, WI. Wauwatosa, WI.

Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung


Conditions: Lung Cancer Adenocarcinoma, Lung Cancer Squamous Cell|, Mesothelioma

Last Updated: February 8, 2022

Status: Recruiting

Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity


Conditions: Carcinoma, Carcinoma, Renal Cell, Endometrial Neoplasms, Mesothelioma, Carcinoma, Non-Small-Cell Lung

Last Updated: January 31, 2022

Status: Recruiting

A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: January 28, 2022

Status: Recruiting

Locations: Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. Uniondale, NY.

eRAPID: Online Symptom Reporting in Lung Cancer


Conditions: Lung Neoplasms, Small Cell Lung Carcinoma, Mesothelioma

Last Updated: January 27, 2022

Status: Recruiting

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma


Conditions: Lung Neoplasms, Mesothelioma, Mesothelioma, Malignant

Last Updated: January 26, 2022

Status: Recruiting

Locations: Cleveland, OH. Philadelphia, PA. Nashville, TN.

Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis


Conditions: Mesothelioma, Carcinoma, Peritoneal Neoplasms, Pseudomyxoma Peritonei

Last Updated: January 24, 2022

Status: Recruiting

Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma


Conditions: Malignant Peritoneal Mesothelioma

Last Updated: January 14, 2022

Status: Recruiting

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery


Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms

Last Updated: January 5, 2022

Status: Recruiting

Locations: Houston, TX.

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors


Conditions: Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma, SCLC, Mesothelioma, Neuroendocrine Tumors, Colorectal Neoplasms, Endometrial Carcinoma, Carcinoma, Ovarian Epithelial, Pancreatic Adenocarcinoma

Last Updated: December 2, 2021

Status: Recruiting

Locations: Boston, MA. Boston, MA.

A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat


Conditions: Lymphoma, Neoplasms, Sarcoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Mesothelioma, Hematologic Neoplasms, Rhabdoid Tumor, Sarcoma, Synovial, Carcinoma, Medullary

Last Updated: December 15, 2021

Status: Recruiting

Locations: Encinitas, CA. Los Angeles, CA. Chicago, IL. Grand Rapids, MI. Canton, OH. Cincinnati, OH. Dallas, TX.

Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: December 9, 2021

Status: Recruiting

Locations: Tampa, FL. Boston, MA. Rochester, MN. Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. Rockville Centre, NY. Sleepy Hollow, NY. Uniondale, NY. Houston, TX.

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant, Wilms Tumor

Last Updated: December 8, 2021

Status: Recruiting

Locations: Basking Ridge, NJ. Middletown, NJ. Commack, NY. Harrison, NY. New York, NY. Uniondale, NY.

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: December 2, 2021

Status: Recruiting

Locations: Birmingham, AL. Phoenix, AZ. Scottsdale, AZ. Duarte, CA. La Jolla, CA. Los Angeles, CA. Los Angeles, CA. Newport Beach, CA. Aurora, CO. Aventura, FL. Coral Gables, FL. Deerfield Beach, FL. Jacksonville, FL. Miami, FL. Miami, FL. Plantation, FL. Chicago, IL. Chicago, IL. Lexington, KY. Baltimore, MD. Baltimore, MD. Boston, MA. Boston, MA. Rochester, MN. Creve Coeur, MO. Saint Louis, MO. Saint Louis, MO. Saint Peters, MO. Durham, NC. Pittsburgh, PA. Dallas, TX. Salt Lake City, UT.

Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: December 2, 2021

Status: Recruiting

Locations: Rochester, MN.

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: November 6, 2021

Status: Recruiting

Locations: Boston, MA. Rochester, MN.

Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)


Conditions: Mesothelioma, Mesothelioma, Malignant, Carcinoma, Peritoneal Neoplasms

Last Updated: November 4, 2021

Status: Recruiting

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations


Conditions: Mesothelioma

Last Updated: November 2, 2021

Status: Recruiting

Locations: Chicago, Illinois. Boston, Massachusetts. Boston, Massachusetts. Houston, Texas. San Antonio, Texas.

Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed


Conditions: Mesothelioma, Carcinoma, Peritoneal Neoplasms, Pseudomyxoma Peritonei, Hyperthermia, Fever

Last Updated: October 15, 2021

Status: Recruiting

UNITO-001-A Phase II Study in HRR/PDL1 Positive MPM/NSCLC


Conditions: Mesothelioma

Last Updated: October 14, 2021

Status: Recruiting

A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: October 4, 2021

Status: Recruiting

Short Neoadjuvant Hemithoracic IMRT for MPM


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: October 4, 2021

Status: Recruiting

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors


Conditions: Carcinoma, Breast Neoplasms, Carcinoma, Squamous Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms, Mesothelioma, Squamous Cell Carcinoma of Head and Neck

Last Updated: October 3, 2021

Status: Recruiting

PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis


Conditions: Carcinoma, Peritoneal Neoplasms

Last Updated: September 21, 2021

Status: Recruiting

Dose Individualization of Pemetrexed - IMPROVE-II


Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant

Last Updated: September 14, 2021

Status: Recruiting

Dose Individualization of Pemetrexed - IMPROVE-III


Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant

Last Updated: September 14, 2021

Status: Recruiting

Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies


Conditions: Neoplasms, Peritoneal Neoplasms

Last Updated: September 13, 2021

Status: Recruiting

Locations: Boston, MA.

Real World Study of MPM in China


Conditions: Mesothelioma, Mesothelioma, Malignant Pleural

Last Updated: September 13, 2021

Status: Recruiting

Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies


Conditions: None

Last Updated: September 13, 2021

Status: Recruiting

Locations: Boston, MA.

A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: September 5, 2021

Status: Recruiting

Locations: Ventura, CA.

Cardiac MRI Biomarker Testing (GCC 1618)


Conditions: Mesothelioma, Thymus Neoplasms

Last Updated: August 16, 2021

Status: Recruiting

Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors


Conditions: Carcinoma, Breast Neoplasms, Melanoma, Carcinoma, Squamous Cell, Adenocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Mesothelioma, Cholangiocarcinoma, Squamous Cell Carcinoma of Head and Neck, Endometrial Neoplasms, Adenocarcinoma of Lung, Thyroid Neoplasms, Esophageal Neoplasms, Cystadenocarcinoma, Carcinosarcoma, Urinary Bladder Neoplasms, Adenomyoepithelioma, Adenocarcinoma, Clear Cell, Cystadenocarcinoma, Serous

Last Updated: August 13, 2021

Status: Recruiting

Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: August 9, 2021

Status: Recruiting

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors


Conditions: Uterine Cervical Neoplasms, Mesothelioma, Carcinoma, Non-Small-Cell Lung, Thymoma, Thymus Neoplasms

Last Updated: July 31, 2021

Status: Recruiting

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II


Conditions: Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant

Last Updated: July 23, 2021

Status: Recruiting

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: July 21, 2021

Status: Recruiting

Locations: Tampa, FL. Baltimore, MD. Detroit, MI. Minneapolis, MN.

Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies


Conditions: Pseudomyxoma Peritonei, Colorectal Carcinoma, Mesothelioma, Ovarian Carcinoma, Peritoneal Neoplasms

Last Updated: July 21, 2021

Status: Recruiting

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: July 19, 2021

Status: Recruiting

A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: June 30, 2021

Status: Recruiting

Locations: Chicago, IL.

The IMmunotherapy Pleural 5-ALA PDT


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: May 18, 2021

Status: Recruiting

Olaparib in Patients With HRD Malignant Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: May 12, 2021

Status: Recruiting

Locations: Chicago, IL.

Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy


Conditions: Stomach Neoplasms, Esophageal Neoplasms, Mesothelioma, Gastrointestinal Stromal Tumors, Anus Neoplasms, Pancreatic Neoplasms, Liver Neoplasms, Carcinoma, Hepatocellular, Gastrointestinal Neoplasms

Last Updated: May 12, 2021

Status: Recruiting

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: April 30, 2021

Status: Recruiting

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: April 30, 2021

Status: Recruiting

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors


Conditions: Carcinoma, Melanoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Mesothelioma, Mesothelioma, Malignant, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Breast Neoplasms, Lung Neoplasms, Carcinoma, Basal Cell, Squamous Cell Carcinoma of Head and Neck, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Neuroendocrine, Thymoma, Small Cell Lung Carcinoma, Anus Neoplasms, Vulvar Neoplasms

Last Updated: April 28, 2021

Status: Recruiting

Locations: Los Angeles, CA. Los Angeles, CA. San Diego, CA. San Francisco, CA. Atlanta, GA. Chicago, IL. Fairway, KS. Detroit, MI. New York, NY. New York, NY. Portland, OR. Philadelphia, PA. Pittsburgh, PA. Houston, TX. Salt Lake City, UT. Charlottesville, VA. Seattle, WA.

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors


Conditions: Carcinoma, Merkel Cell, Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Squamous Cell, Ovarian Neoplasms, Carcinoma, Hepatocellular, Stomach Neoplasms, Uterine Cervical Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Mesothelioma, Mesothelioma, Malignant, Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Anus Neoplasms, Thymus Neoplasms, Microsatellite Instability

Last Updated: April 15, 2021

Status: Recruiting

Locations: New Haven, CT. Houston, TX.

Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: April 12, 2021

Status: Recruiting

Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma


Conditions: Lymphoma, Carcinoma, Prostatic Neoplasms, Leukemia, Myeloid, Melanoma, Carcinoma, Squamous Cell, Leukemia, Myeloid, Acute, Ovarian Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Stomach Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Mesothelioma, Malignant, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Adenoid Cystic, Thymoma, Lung Neoplasms

Last Updated: March 11, 2021

Status: Recruiting

Locations: Duarte, CA. Morristown, NJ. New York, NY. Houston, TX. Milwaukee, WI.

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S


Conditions: Neoplasm Metastasis, Brain Neoplasms, Astrocytoma, Mesothelioma, Cholangiocarcinoma, Esophageal Neoplasms, Tongue Neoplasms, Thymoma, Urologic Neoplasms

Last Updated: March 8, 2021

Status: Recruiting

Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: March 5, 2021

Status: Recruiting

Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: March 2, 2021

Status: Recruiting

Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: February 26, 2021

Status: Recruiting

Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies


Conditions: Mesothelioma, Mesothelioma, Malignant, Disease Progression

Last Updated: February 26, 2021

Status: Recruiting

Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: February 25, 2021

Status: Recruiting

DENdritic Cell Immunotherapy for Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: January 27, 2021

Status: Recruiting

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma


Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant

Last Updated: January 22, 2021

Status: Recruiting

Autologous Dendritic Cell Vaccination in Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: January 19, 2021

Status: Recruiting

Rehabilitation by Effort for Patients With Advanced Bronchial Cancer


Conditions: Mesothelioma, Mesothelioma, Malignant, Carcinoma, Bronchogenic

Last Updated: July 29, 2020

Status: Recruiting

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors


Conditions: Mesothelioma

Last Updated: July 28, 2020

Status: Recruiting

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant, Hyperthermia

Last Updated: July 14, 2020

Status: Recruiting

HMPL-453 in Advanced Malignant Mesothelioma


Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms

Last Updated: June 16, 2020

Status: Recruiting

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours


Conditions: Mesothelioma, Neuroendocrine Tumors, Thymoma

Last Updated: May 5, 2020

Status: Recruiting

Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed


Conditions: Mesothelioma

Last Updated: December 13, 2019

Status: Recruiting

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies


Conditions: Leukemia, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Mesothelioma, Sarcoma, Synovial, Esophageal Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms

Last Updated: December 11, 2019

Status: Recruiting

Mesothelioma and Radical Surgery 2


Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: October 28, 2019

Status: Recruiting

International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)


Conditions: Mesothelioma, Pancreatic Neoplasms, Gallbladder Neoplasms, Pseudomyxoma Peritonei, Appendiceal Neoplasms, Pleural Effusion, Ascites

Last Updated: October 7, 2019

Status: Recruiting

uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung


Conditions: Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Mesothelioma, Malignant, Carcinoma, Neuroendocrine

Last Updated: November 21, 2016

Status: Recruiting